Browsing by Author "Batista, Leopoldina Maria Melo"

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.
    (2004) Borja Cabrera, Gulnara Patricia; Mendes, Amanda Cruz; Souza, Edilma Paraguai de; Okada, Lilian Y. Hashimoto; Trivellato, Fernando Antonio de Assis; Kawasaki, Jarbas Kiyoshi Alves; Costa, Andreia Cerqueira; Reis, Alexandre Barbosa; Genaro, Odair; Batista, Leopoldina Maria Melo; Palatnik, Marcos; Souza, Clarisa Beatriz Palatnik de
    The potential effect of the fucose mannose ligand (FML)-vaccine on immunotherapy of canine visceral leishmaniasis was assayed on five mongrel dogs experimentally infected withLeishmania donovani and on 21 Leishmania chagasi naturally infected dogs when seropositive to FML but completely asymptomatic. The clinical signs of the experimentally infected, symptomatic dogs only disappeared after the complete vaccination. Protection was obtained in 3/5 animals that remained asymptomatic, IDR positive and parasite free, 1 year after infection. Furthermore, the asymptomatic, FML-vaccine treated dogs showed stable anti-FML IgG1 levels, increasing IgG2 levels and 79–95% of positive DTH response, during the whole experiment. Twenty-two months after complete vaccination, no obits due to visceral leishmaniasis were recorded and 90% of these dogs were still asymptomatic, healthy and parasite free. On the other hand, 37% (17/46 dogs) kala-azar obits were recorded in a control group that received no treatment during the same period, and that was FML-seropositive and asymtpomatic at the beginning of the assay. Our results indicate that the FML-vaccine was effective in the immunotherapy against visceral leishmaniasis of asymptomatic infected dogs. Normal proportions of CD4 and CD21 lymphocytes were detected in PBMC by FACS analysis, in dogs submitted to immunotherapy, suggesting their non-infectious condition. All animals showed as well significantly increased percents of CD8 lymphocytes as expected for Quillajasaponin (QuilA) vaccine treatments.